OR WAIT null SECS
Charles River Laboratories has announced a data expansion in its compendium of tumor models for oncology drug R&D.
A new addition to the Tumor Model Compendium provides access to an expanded collection of tumor models for early stage oncology research, noted Charles River Laboratories International, in a Nov. 13, 2018 press release.
The most recent update to the Compendium adds gastric and liver models as well as new molecular data for leukemia, liver cancer, lymphoma, breast cancer, and ovarian cancer. These additions provide oncology researchers access to data that allows identification of the most appropriate tumor models, which in turn can lead to a more targeted study design at the outset, reportedly saving time and money on the path to the clinic, according to Charles River.
The Compendium includes tumor models from a wide range of tumor subtypes for both in-vivo and in-vitro oncology research, including patient-derived xenografts (PDXs), cell line-derived xenografts (CDX), and syngeneic models.
“Our scientists have worked diligently to accelerate cancer research and anticancer drug development efforts so patients can get the treatments they desperately need,” said Birgit Girshick, corporate executive vice-president, discovery and safety assessment, Charles River, in the company press release.
“Since its inception, our Tumor Model Compendium has made finding the best research model for oncology research easier. We are excited about the latest additions and are proud to offer this important resource to oncology researchers,” added Julia Schueler, research director, Charles River.